date,title,source
Oct-23-18,Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 until October 2033,GlobeNewswire
Nov-13-18,VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20,GlobeNewswire
Nov-16-18,VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting,GlobeNewswire
